Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorKorea University Anam Hospital

About this trial

This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is non-inferior to monotherapy in stabilizing coronary plaques over 52 weeks. The primary endpoint is the percentage change in coronary atheroma volume (PAV) assessed by grayscale IVUS, with secondary outcomes including changes in lipid core burden, inflammatory markers, and clinical events like myocardial infarction and ischemic stroke. The study plans to enroll 408 patients undergoing coronary intervention across 7 domestic institutions, with rigorous follow-up protocols and adherence to international research guidelines.

Eligibility criteria

Qualifiers

Adult men and women over the age of 18 years.

Patients with coronary artery disease undergoing a coronary intervention procedure using intravascular imaging.

Angiographic evidence of coronary artery stenosis ≥30% by angiographic visual estimation.

Target vessel is accessible to the imaging catheter and suitable for intracoronary imaging in the proximal 50 mm segment.

Disqualifiers

Left main stem lesion: Left main coronary artery stenosis ≥50% by coronary angiographic visual estimation.

History of coronary artery bypass graft surgery (CABG).

Unstable clinical condition (hemodynamic or electrical instability).

Severe coronary artery calcification or tortuosity interfering with IVUS, NIRS, or evaluation.

Trial design

Treatments tested in this trial

  • statins, ezetimibe
  • Combination therapy

Treatment groups

408 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Korea University Anam Hospital

Lead sponsor

Yuhan Corporation

Collaborator

Hanmi Pharmaceutical co., ltd.

Collaborator